Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis. The gene discussed is NOTCH1; the disease is intrahepatic cholangiocarcinoma.